A heparin-like anticoagulant as part of global abnormalities of plasma glycosaminoglycans in a patient with transitional cell carcinoma.
A patient is described in whom a circulating heparin-like anticoagulant developed during the terminal course of metastatic transitional cell carcinoma. The anticoagulant, which was identified as heparan sulfate, was the clinical sign of global abnormalities in the patient's plasma glycosaminoglycans. Subsequent analysis disclosed increased amounts of chondroitin sulfate as well as heparan sulfate. In addition, the charge density and molecular weight of the patient glycosaminoglycans and their organization into proteoglycans differed significantly from glycosaminoglycans isolated from normal plasma samples.
Horne
M K
MK
Hematology Section, National Institutes of Health, Bethesda, MD 20892.
Chao
E S
ES
Wilson
O J
OJ
Scialla
S J
SJ
Lynch
M A
MA
Kragel
P J
PJ
D000368:Aged; D000925:Anticoagulants / Q000097:blood*; D001780:Blood Coagulation Tests; D002295:Carcinoma, Transitional Cell / Q000097:blood*; D002845:Chromatography; D002850:Chromatography, Gel; D004588:Electrophoresis, Cellulose Acetate; D005260:Female; D006025:Glycosaminoglycans / Q000097:blood* / Q000302:isolation & purification; D006493:Heparin / Q000097:blood*; D006801:Humans; D012016:Reference Values; D014565:Urogenital Neoplasms / Q000097:blood*
D000925:Anticoagulants; D006025:Glycosaminoglycans; D006493:Heparin